Essential Drugs Production in Brazil, Russia, India, China and South Africa (BRICS): Opportunities and Challenges

Document Type: Review Article

Author

1 Higher Colleges of Technology, Al Ain, UAE

2 The Wharton Entrepreneurship and Family Business Research Centre, University of Pennsylvania, CERT Technology Park, Abu Dhabi, UAE

Abstract

The objective of this work is to elucidate various essential drugs in the Brazil, Russia, India, China and South Africa (BRICS) countries. It discusses the opportunities and challenges of the existing biotech infrastructure and the production of drugs and vaccines in member states of the BRICS. This research is based on a systematic literature review between the years 2000 and 2014 of documents retrieved from the databases Embase, PubMed/Medline, Global Health, and Google Scholar, and the websites of relevant international organizations, research institutions and philanthropic organizations. Findings vary from one member state to another. These include useful comparison between the BRICS countries in terms of pharmaceuticals expenditure versus total health expenditure, local manufacturing of drugs/vaccines using technology and know-how transferred from developed countries, and biotech entrepreneurial collaborations under the umbrella of the BRICS region. This study concludes by providing recommendations to support more of inter collaborations among the BRICS countries as well as between BRICS and many developing countries to shrink drug production costs. In addition, this collaboration would also culminate in reaching out to poor countries that are not able to provide their communities and patients with cost-effective essential  medicines.

Keywords

Main Subjects


1. Harmer A, Xiao Y, Missoni E, Tediosi F. ‘BRICS without straw’? A systematic literature review of newly emerging economies’ influence in global health. Global Health 2013; 9: 15. doi: 10.1186/1744-8603-9-15

2. Harmer A, Folayinka D, Lesong C. The BRICS: what is their contribution to global health? A Global Village 2013; 9: 34-7.

3. Hau M, Scott J, Hulme D. Beyond the BRICs: alternative strategies of influence in the global politics of development. Eur J Dev Res 2012; 24: 187-204. doi: 10.1057/ejdr.2012.6

4. Petrie D, Tang KK. Relative health performance in BRICS over the past 20 years: the winners and losers. Bull World Health Organ 2014; 92: 396-404. doi: 10.2471/blt.13.132480

5. World Economic and Financial Surveys. World Economic Outlook Database [internet]. [cited 2013 November 5].Available from: http://www.imf.org/external/pubs/ft/weo/2013/01/weodata/index.aspx

6. Passarelli C, Pimenta C, Danishevskiy K, Singh S, Yan G, Kaufman J. Shifting paradigm: How the BRICS are reshaping global health and development, Global Health Strategies initiatives (GHSi) [internet]. [cited 2013 October 21].Available from: http://www.eldis.org/go/display&t

ype=Document&id=63081#.UhXdGX-Yfo8

7. Harmer A, Buse K. The BRICS – a paradigm shift in global health? Contemporary Politics 2014; 20: 127-45. doi: 10.1080/13569775.2014.907988

8. Kirton J, Kulik J, Bracht C. Generating global health governance through BRICS summitry. Contemporary Politics 2014; 20: 146-62. doi: 10.1080/13569775.2014.907990

9. Rao SG, Thomas D, Zachariah S, Kannan MS, Alvarez-Uria G. Comparison of essential drug list in a rural secondary care hospital in south India with Indian & World Health Organization list 2011. Indian J Physiol Pharmacol 2012; 56: 375-81.

10. Chen W, Tang S, Sun J, Ross-Degnan D, Wagner AK. Availability and use of essential medicines in China: manufacturing, supply, and prescribing in Shandong and Gansu provinces. BMC Health Ser Res 2010; 10: 211. doi: 10.1186/1472-6963-10-211

11. Kaddar M, Milstien J, Schmitt S. Impact of BRICS’ investment in vaccine development on the global vaccine market. Bull World Health Organ 2014; 92: 436-46. doi: 10.2471/blt.13.133298

12. Sáenz TW, Souza-Paula MC, Melon CM, Ray M, Thorsteinsdóttir H. Setting a southern course: Brazil’s south-south collaboration in health biotech. In: Thorsteinsdóttir H, editor. South-South Collaboration in Health Biotechnology: Growing Partnerships amongst Developing Countries. Ottawa: IDRC & Academic Foundation; 2012. p. 99-121.

13. Chaturvedi S, Thorsteinsdóttir H. BRICS and south-south cooperation in medicine: Emerging trends in research and entrepreneurial collaborations[internet].2012.[cited 2013 July 10].  Available from:http://www.ris.org.in/images/RIS_images/pdf/dp177_pap.pdf

14. Aly S, Madkour MA, Maram H, Adly N. Learning through collaborations: Egypt’s south-south health biotechnology collaboration. In: Thorsteinsdóttir H, editor. South-south collaboration in health biotechnology: Growing partnerships amongst developing countries. Ottawa: IDRC & Academic Foundation; 2012. p. 153-72.

15. Access Campaign. MSF calls on BRICS countries to prioritize health and access to medical innovation [internet]. [cited 2014 August 18]. Available from:  http://www.msfaccess.org/

content/msf-calls-brics-countries-prioritize-health-and-access-medical-innovation

16. Liao, K. BRICS Nations Team to Strengthen Health Sector [internet]. [cited 2014 January 20].  Available from: 

http://www.borgenmagazine.com/ brics-nations-team-strengthen-health-sector/

17. [No author listed]. Special theme:  BRICS and the global health 2014. Bull World Health Organ 2014; 92: 385. doi: 10.2471/BLT.14.000614

18. Timmermans K. Ensuring access to medicines in 2005 and beyond [internet].[cited 2013 July 25]. Available from: http://www.tansey.org.uk/docs/neg-health-intro.pdf

19. Rovira, J. Creating and promoting domestic drug manufacturing capacities: A solution for developing countries [internet].2006. [cited 2013 November 25]. Available from: https://www.unido.org/fileadmin/user_media/

Services/PSD/BEP/Rovira_Negotiating%20Health_2006.PDF

20. Yu P. Access to medicines, BRICS alliances, and collective action. Am J Law Med 2008; 34: 345-94.

21. Laidi Z. BRICS: Sovereignty power and weakness. Int Politics 2012; 49: 614-32. doi: 10.1057/ip.2012.17

22. Yu PK. Access to medicines, BRICS alliances, and collective action. Am J Law Med 2008; 34: 345-94.

23. World Health Organization (WHO). Global Health Observatory (GHO) [internet].[cited 2013 November 25].  Available from: http://www.who.int/gho/countries/bra/en/

24. Ross C. Building BRICs: Pharma’s key emerging markets are becoming giants [internet].[cited 2013 August 5]. Available from: http://www.pmlive.com

/pharma_intelligence/building_brics_pharmas_key_emerging_markets_are_becoming_giants_483972

25. Ernst & Young’s 2012 attractiveness survey in Russia 2012 [internet].[cited 2012 November 5]. Available from: http://emergingmarkets.ey.com/wp-content/uploads/downloads/2012/09/RAS_2012_2012_09.06_FINAL.pdf

26. United Nations Industrial Development Organization (UNIDO). Italy funds AIDS project in South Africa [internet].[cited 2013 June 29]. Available from:  http://www.manufacturingchemist.com/

news/article_page/Italy_funds_AIDS_project_in_South_Africa/76154

27. MBendi. Pharmaceutical and Medicine Manufacturing in South Africa [internet].[cited 2013 November 13]. Available from: http://www.mbendi.com/indy/chem/phrm/af/sa/p0005.htm

28. Amuasi JH. Technology transfer and local manufacturing of pharmaceuticals: The South African case [internet]. [cited 2013 December 9].  Available from: http://ictsd.org/downloads/2009/12/amuasi-paper-edited.pdf

29. Maloney C, Segal N. The Growth Potential of the Pharmaceuticals Sector in South Africa. South Africa, Johannesburg: Genesis Analytics (Pty) Ltd; 2007.

30. Almeida C, Pires de Campos R, Buss P, Ferreira JR, Fonseca LE. Brazil’s conception of south-south “structural cooperation” in health. Global Forum Update on Research for Health 2010;4: 23-32.

31. Health Cooperation: Brazilian International Health Activities Bulletin [internet].2010. Available from: http://portal.saude.gov.br/portal/arquivos/pdf/Boletim_AISA_ING_alta.pdf

32. Chaudhuri S, Mackintosh M, Mujinja PG. Indian generics producers, access to essential medicines and local production in Africa: an argument with reference to Tanzania. European Journal of Development Research 2010; 22: 451-68. doi: 10.1057/ejdr.2010.27

33. Serruya SJ, Guimarães R, de Albuquerque IO, Morel CM. Research and innovation in Brazil: The institutional role of the ministry of health. Global Forum Update on Research for Health 2008;5: 24-7.

34. Novaratis. Novartis completes acquisition of majority stake in Zhejiang Tianyuan expanding vaccines presence in China [internet].2014. [cited 2014 February 2]. Available from: http://www.reuters.com/article/2011/03/22/idUS50620+22-Mar-2011+HUG20110322

35. KPMG. China’s Pharmaceutical Industry – Poised for the giant leap [internet]. [cited 2013 March 15]. Available from: http://www.kpmg.com/

cn/en/issuesandinsights/articlespublications/pages/china-pharmaceutical-201106.aspx

36. Wassener B. In China, Strong Debut for Supplier of Heparin. The New York Times [serial on the internet.2010. Available from: http://www.nytimes.com/2010/05/07/business/global/07drug.html?_r=0

37. Jiangsu Hengrui [internet].2013. Available from: http://www.hrs.com.cn/english/

38. Kresge N. China’s Thirst for New Diabetes Drugs Threatens Bayer’s Lead [internet].2011. Available from: http://www.bloomberg.com/

news/2011-11-20/china-s-thirst-for-new-diabetes-drugs-threatens-bayer-s-lead.html

39. Techpool [home page on the internet].2013. Available from: http://www.techpool.com.cn/index_en.html

40. Frew SE, Kettler HE, Singer PA. The Indian and Chinese Health Biotechnology Industries: Potential Champions Of Global Health? Health Aff (Millwood) 2008; 27: 1029-41. doi: 10.1377/hlthaff.27.4.1029

41. Burki TK. BRICS nations tackle non-communicable diseases. Lancet Oncol 2012; 13: 451. doi: 10.1016/s1470-2045(12)70151-1

42. Elbeshbishi AN. TRIPS and public health: What should African countries do? ATPC Work in progress No. 49. Addis Ababa: Economic Commission for Africa; 2007.

43. Yusuf S, Nabeshima K, Perkins DH. China and India Reshape Global Industrial Geography. In: Winters A, Yusuf S, editors. Dancing with Giants-China, India, and the Global Economy. Washington and Singapore: The World Bank and the Institute of Policy Studies; 2007. p. 35-66.

44. World Health Organization (WHO). Public health, innovation and intellectual property rights. [internet].2006. Available from: http://www.who.int/intellectualproperty/report/en/

45. Rao KD, Petrosyan V, Araujo E C, McIntyre D. Progress towards universal health coverage in BRICS: translating economic growth into better health. Bull World Health Organ 2014; 92: 429-35. doi: 10.2471/blt.13.127951

46. Zandi L. Technology Transfer and Business Partnerships in BRICS: Development, Integration and Industrialization. Mediterranean Journal of Social Sciences 2014; 5: 284-93. doi: 10.5901/mjss.2014.v5n7p284

47. Littlejohns P. Banking on the BRICS for health? Lancet 2013; 381: 1158. doi: 10.1016/s0140-6736(13)60781-3

48. Shamik D. At last, some good news about the world economy. Management Today 2012;  7: 26-7.

49. Tseng CY. Technological Innovations in the BRIC Economies. Research Technology Management 2009; 52: 29-35.

50. Council on Health Research for Development (COHRED) and New Partnership for Africa’s Development (NEPAD). Strengthening pharmaceutical innovation in Africa: Designing strategies for national pharmaceutical innovation: Choice for decision makers and countries [internet].[cited 2013 July 21]. Available from: http://www.policycures.org/downloads/COHRED-NEPAD_Strengthening_Pharmaceutical_Innovation_AfricaREPORT.pdf